CNBC's Jim Cramer talks about the importance of doing one's homework. On November 9, a caller asked Jim about Regeneron Pharmaceuticals Inc. Cramer told him that he’d rather see investors in any of his cancer-related biotech spec stocks. We fell out of our chairs. Regeneron was a great speculative pick that day. The very next day Regeneron skyrocketed 25% on news that Regeneron and Sanofi-Aventis had expanded their partnership to develop a number of Regeneron's experimental drugs.
The caller was obviously following the action better than Jim. We recommend searching our news archive to find potential winners and losers. You'll find business decisions and US FDA actions that can help predict where a company's stock is headed, like Targacept up 800% in 3 months.